AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25055933
Drug: Intracervical dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical dinoprostone (0.5 mg every 2 h, maximum of 2 doses)
Trial: 25055933
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol and intracervical dinoprostone
Trial: 22151932
Drug: Lignin peroxidase
RxNorm normalized name: peroxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignin peroxidase cream (LIP)
Trial: 19187507
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14)
Trial: 15289368
Drug: Dalteparin 5000
RxNorm normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 5000 IU daily
Trial: 16206671
Drug: Hydrotalcite 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrotalcite 1.0 g four times daily for 6 weeks
Trial: 16206671
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily for the first 2 weeks and 20 mg once daily for the following 4 weeks
Trial: 9738364
Drug: Ibuprofen L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen L-arginine 400 mg
Trial: 9738364
Drug: Naproxen 550
RxNorm normalized name: naproxen sodium 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 550 mg
Trial: 2468894
Drug: Potassium (KCl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium (KCl, 20 mEq three times daily)
Trial: 2468894
Drug: Calcium (Ca,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (Ca, 500 mg twice daily)
Trial: 30239887
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (HDC) - mean initial dose 100 mg/m2
Trial: 30239887
Drug: Low-dose cisplatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cisplatin (LDC) - mean initial dose 40 mg/m2
Trial: 21665059
Drug: Support-person intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Support-person intervention (written materials plus three weekly telephone sessions lasting 10-30 minutes each)
Trial: 15320990
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rev, tat, and nef intramuscularly at weeks 0, 4, and 16 at increasing doses (300, 900, and 1800 micrograms DNA)
Trial: 15320990
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rev, tat, and nef intramuscularly
Trial: 15320990
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rev, tat, and nef in increasing doses
Trial: 9330391
Drug: Japanese herbal
RxNorm normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese herbal medicine (Juzentaihotou or Hotyuekkitou)
Trial: 3878905
Drug: 1,25(OH)2D3 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3 treatment for a mean of 16.8 ± 6.4 months
Trial: 24826396
Drug: Novel ALA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel ALA (5-aminolevulinic acid) treatment, 2 treatments 2 weeks apart
Trial: 16081585
Drug: Montelukast (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (oral, 10 mg/day) combined with inhaled Budesonide (400 microg/bid)
Trial: 12069111
Drug: Antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy based on idebenone
Trial: 12069111
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 plus Vitamin E administration
Trial: 9578859
Drug: Usual breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual breast screening invitation accompanied by a self administered questionnaire
Trial: 1804010
Drug: Cefepime (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2.0 g intravenously twice daily for 4 to 28 days)
Trial: 1804010
Drug: Ceftazidime (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2.0 g every 8 h)
Trial: 6228347
Drug: Intranasal ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal ipratropium
Trial: 31496381
Drug: Ultrasound-guided quadratus
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided quadratus lumborum block (QLB) with 10 ml of 0.5% bupivacaine and 10 ml of 2% lidocaine before ESWL
Trial: 26444149
Drug: 0.3 μg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 μg.kg(‐1) dexmedetomidine
Trial: 26444149
Drug: 1 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg.kg(‐1) propofol
Trial: 15794869
Drug: Oral chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chlorambucil at a dose of 8 mg/m² (6 mg/m² for those > 75 years of age) for 10 days every 28 days to a maximum of 12 cycles
Trial: 15794869
Drug: Oral or
RxNorm normalized name: Doral Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or intravenous (I.V.) fludarabine at a dose of 40 mg/m² orally or 25 mg/m² I.V. (30 mg/m² orally or 20 mg/m² I.V. for those > 75 years of age) for 5 days every 28 days to a maximum of 6 cycles
Trial: 12872394
Drug: Fluticasone inhalation
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone inhalation combined with XQLD
Trial: 12872394
Drug: Fluticasone inhalation
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone inhalation
Trial: 9160568
Drug: Intravenous caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous caffeine (3, 5, and 7 mg/kg)
Trial: 2690914
Drug: Oral fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral fluorouracil 500 mg, methotrexate 25 mg and chlorambucil 10 mg p.o. on day 1 and fluorouracil 500 mg and chlorambucil 10 mg p.o. on day 2 (LMF) every 21 days for eight cycles.
Trial: 971343
Drug: Secholex (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secholex (15 g/day)
Trial: 971343
Drug: Secholex (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secholex (9 g/day)
Trial: 25781384
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg IV
Trial: 16365070
Drug: Regular wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular wheat bread and cholecalciferol supplement (vitamin D control)
Trial: 10827226
Drug: MARS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MARS treatment in addition to hemodiafiltration (HDF) and standard medical therapy
Trial: 10827226
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (HDF and standard medical treatment alone)
Trial: 8770960
Drug: Supraphysiologic dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiologic dose B-vitamin supplementation (15 mg folic acid/day, 100 mg B-6/day, 1 mg B-12/day)
Trial: 8770960
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (1 mg folic acid, 10 mg B-6, 12 micrograms B-12)
Trial: 8770960
Drug: Supraphysiologic dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiologic dose B-vitamin supplementation
Trial: 1608903
Drug: 75 ml
RxNorm normalized name: ethanol 0.75 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 ml of alcohol (94%) in 75 ml of orange juice
Trial: 1608903
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml of orange juice
Trial: 20373908
Drug: I-neb AAD
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-neb AAD System with Target Inhalation Mode (TIM)
Trial: 12449165
Drug: MPA (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA (30 mg b.i.d.)
Trial: 12449165
Drug: ACET (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACET (250 mg b.i.d.)
Trial: 8523872
Drug: Duraflo II
RxNorm normalized name: Duraflor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duraflo II bonded heparin coated circuit
Trial: 1686197
Drug: Novel anxiolytic/hypnotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel anxiolytic/hypnotic compound
Trial: 7145555
Drug: High-dose split-product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose split-product vaccine (SPV) containing 7, 7, and 60 micrograms of hemagglutinins (HA)
Trial: 7145555
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose split-product vaccine (SPV) containing 7, 7, and 7 micrograms of HA
Trial: 7145555
Drug: High-dose split-product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose split-product vaccine (SPV)
Trial: 7145555
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose split-product vaccine (SPV)
Trial: 31478938
Drug: Patient-controlled sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled sedation (PCS) with propofol (PCS-G group)
Trial: 28176175
Drug: Standard neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard neoadjuvant therapy
Trial: 21893151
Drug: 2-doses of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-doses of PCV7(CRM197)
Trial: 21893151
Drug: 2+1-doses of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2+1-doses of PCV7(CRM197)
Trial: 14706012
Drug: Cholinergic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic therapy (bethanechol chloride 60 mg/day or distigmine bromide 15 mg/day)
Trial: 14706012
Drug: Alpha-blocker therapy
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker therapy (urapidil 60 mg/day)
Trial: 14706012
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (cholinergic drug and alpha-blocker)
Trial: 14706012
Drug: Cholinergic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic therapy (control)
Trial: 14706012
Drug: Alpha-blocker therapy
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker therapy (control)
Trial: 11676116
Drug: Butenafine (1%)
DrugBank: Butenafine (DB01091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Butenafine (1%) cream applied for 4 weeks for tinea pedis and 2 weeks for tinea cruris and tinea corporis
Trial: 11038765
Drug: Intraperitoneal (i.p.)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (i.p.) carboplatin chemotherapy
Trial: 11038765
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) carboplatin chemotherapy
Trial: 7946939
Drug: Oral isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosorbide dinitrate (ISDN; 20 mg twice daily for 2 weeks)
Trial: 31838920
Drug: Amoxicillin/clavulanate for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate for 4 weeks and a short course of oral steroids
Trial: 11095598
Drug: Tetracycline (6-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (6-week course, twice daily)
Trial: 3922048
Drug: CaNa2EDTA infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CaNa2EDTA infusion during the first 2 days after admission
Trial: 3922048
Drug: Normal conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal conservative treatment
Trial: 30019751
Drug: Perioperative aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative aspirin
Trial: 26418211
Drug: HiP (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HiP (high protein): parenteral nutrition = 3.5 AA, enteral nutrition = 4.6 protein g·kg·day
Trial: 26418211
Drug: StP (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: StP (standard protein): parenteral nutrition = 2.5 AA, enteral nutrition = 3.6 protein g·kg·day
Trial: 21155337
Drug: Levobupivacaine-fentanyl (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine-fentanyl (3 mg of 0.1% levobupivacaine plus 10 microg of fentanyl)
Trial: 21155337
Drug: Lidocaine-fentanyl (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-fentanyl (18 mg of 0.6% lidocaine plus 10 microg of fentanyl)
Trial: 15295694
Drug: Canarypox HIV‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canarypox HIV‐1 vaccine
Trial: 9831304
Drug: Naltrexone (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (75 mg daily for 12 weeks)
Trial: 2751143
Drug: Oral medication
RxNorm normalized name: Oral Medication Syringe 3mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication (meperidine 3.0 mg/kg, pentobarbital 4.0 mg/kg)
Trial: 2751143
Drug: Intramuscular medication
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular medication (morphine 0.1 mg/kg, pentobarbital 4.0 mg/kg)
Trial: 23074076
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training (RT) intervention for 8 weeks, 8 exercises, 1 set of 10 repetitions at perceived exertion of 5-6, performed twice a week
Trial: 19709691
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose infusion (0.75 g glucose per kilogram body weight for 2.5 hours)
Trial: 15716204
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg daily for 4 weeks, followed by flexible dosing (5 mg or 10 mg)
Trial: 15716204
Drug: Solifenacin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin treatment
Trial: 12072586
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg or 20 mg lercanidipine
Trial: 10086838
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg reboxetine orally
Trial: 10086838
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg reboxetine as an intravenous bolus
Trial: 7985892
Drug: Zidovudine, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine, 600 mg/d
Trial: 7985892
Drug: Zalcitabine, 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalcitabine, 2.25 mg/d
Trial: 7985892
Drug: Zidovudine, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine, 600 mg/d, and zalcitabine, 2.25 mg/d
Trial: 7985892
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (zidovudine and zalcitabine)
Trial: 7985892
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (for patients with 50 to 150 CD4 cells/mm3 or fewer than 50 CD4 cells/mm3)
Trial: 2154407
Drug: Enalapril (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (initial dose, long-term treatment for 1 and 6 weeks)
Trial: 2154407
Drug: Enalapril (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (after first dose)
Trial: 31816842
Drug: Euglena gracilis
RxNorm normalized name: EUGLENA GRACILIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglena gracilis fermentate (BG) 367 mg
Trial: 17845651
Drug: 4% modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% modified gelatine solution
Trial: 15218813
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate treatment over 3 years
Trial: 11451751
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg daily for 6 weeks)
Trial: 2563695
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course metronidazole rectal suppositories
Trial: 26063503
Drug: Clopidogrel 300/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300/75 mg regimen
Trial: 26063503
Drug: Clopidogrel 600/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600/150 mg regimen
Trial: 26063503
Drug: Clopidogrel 300/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300/75 mg regimen and 600/150 mg regimen
Trial: 23151750
Drug: Usual MAP
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual MAP treatment goal (102‐107 mm Hg)
Trial: 23151750
Drug: Low MAP
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low MAP treatment goal (≤92 mm Hg)
Trial: 18485575
Drug: Cizolirtine citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cizolirtine citrate 400 mg bid (C400)
Trial: 18485575
Drug: Cizolirtine citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cizolirtine citrate 200 mg bid (C200)
Trial: 30832581
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (control group).
Trial: 9342586
Drug: Nicotine inhalation
RxNorm normalized name: nicotine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine inhalation at 30 degrees C
Trial: 9342586
Drug: Nicotine inhalation
RxNorm normalized name: nicotine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine inhalation at 40 degrees C
Trial: 9342586
Drug: Nicotine inhalation
RxNorm normalized name: nicotine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine inhalation at 20 degrees C
Trial: 8376688
Drug: Enalapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (2.5 to 20 mg/day)
Trial: 3757162
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg dexamethasone i.v.
Trial: 20363993
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no atorvastatin therapy)
Trial: 19005437
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (700 mg of flavonoids/day for one week)
Trial: 16161727
Drug: Psychotherapy (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy (8 sessions of cognitive behavioral therapy) plus antidepressant pharmacotherapy over 3 months
Trial: 11123120
Drug: NTG patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG patch (n = 6)
Trial: 11123120
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (n = 6)
Trial: 11123120
Drug: NTG patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG patch (n = 5, at H4)
Trial: 11123120
Drug: NTG patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG patch (n = 5, at H23)
Trial: 11123120
Drug: NTG patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG patch (n = 5)
Trial: 7841703
Drug: Buserelin intranasal
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin intranasal spray (group A)
Trial: 3234301
Drug: Al-Mg-silicate preparation
RxNorm normalized name: silicic acid
DrugBank: Silicic acid (DB14138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al-Mg-silicate preparation (MegalacR) administered 45 min after the meal
Trial: 3234301
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with PI without antacid
Trial: 17541571
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral morphine
Trial: 15504996
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin (Exubera) plus bedtime Ultralente
Trial: 15504996
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin regimen (two to three injections of regular and NPH insulin)